RHONDA Q. FREEMAN, PH.D. SUNRISE MEDICAL GROUP 4925 Sheridan St. Suite 200 Hollywood, FL (954)

Transcription

1 RHONDA Q. FREEMAN, PH.D. SUNRISE MEDICAL GROUP 4925 Sheridan St. Suite 200 Hollywood, FL (954) LICENSE: FL #PY 6252 SPECIALTY: EDUCATION: Bachelor of Science (Psychology) June 1992 Master of Science (Neuropsychology) November 1996 Doctor Of Philosophy (Clinical Psychology) Emphasis in Neuropsychology June 1999 POST DOCTORAL FELLOWSHIP: CLINICAL TRAINING: INTERNSHIP: University of Miami School of Medicine/ Mount Sinai Medical Center Wien Center for Memory Disorders and Alzheimer s Disease Miami Beach, FL 9/99-9/00 Riddle Memorial Hospital- Neurobehavioral Unit Media, PA 9/98-9/99 Norristown State Hospital Norristown, PA Forensic Unit 9/97-9/98 Philadelphia Geriatric Center 9/97-9/98 PRACTICUM TRAINING: Crozer-Chester Medical Center Upland, PA 9/96-9/97 Cooper Hospital University Medical Center Camden, NJ Department of Neurology 9/95-9/96

2 Clinical Neuropsychology Associates 9/94-8/99 Magee Rehabilitation Hospital Brain Injury Rehabilitation Unit Psychometrist 9/94-6/95 MEDICAL STAFF AFFILIATIONS: Lee Memorial Hospital The Rehabilitation Hospital Brain Injury & Spinal Cord Unit Ft. Myers, FL Memorial Hospital Pembroke Memory Disorder Center Pembroke Pines, FL 2002 Present EXPERIENCE: Sunrise Medical Group Hollywood, FL Present Sunrise Clinical Research, Inc Hollywood, FL Rater/ SubInvestigator Present Neurology Clinical Research, Inc. Sunrise, FL Present TEACHING EXPERIENCE: Mt. Sinai Medical Center Miami Beach, FL Neuropsychological Lectures 9/99-9/00 Philadelphia College of Osteopathic Medicine Guest Lecturer- Neuroanatomy 4/97-6/97 Teaching Assistant 9/93-9/94 PROFESSIONAL AFFILIATIONS: National Academy of Neuropsychology International Neuropsychological Society

3 PUBLICATIONS: Book Chapter Articles Libon, D.J., Freeman, R.Q., Giovannetti, T., Lamar, M., Cloud, B.S., Stern, R.A., and Kaplan, E. (2002). The Rey- Osterrieth Complex Figure and Visuoconstructional Impairment in Cortical and Subcortical Dementia. In J. Knight & E. Kaplan (Eds), The Rey-Osterrieth Complex Figure: Clinical and Research Application. Odessa, FL: Psychological Assessment Resources. Caregivers Judgments of the Functional Abilities of the Alzheimer s Disease Patient: A Comparison of Proxy Reports and Objective Measures of the Functional Status Loewenstein, DA., Arguelles, S., Bravo, M., Freeman, RQ., Arguelles, T., Acevedo, A., & Eisdorfer, C. Journal of Gerontology,56 (2), (2001) Visuoconstructional Problems in Dementia: Contribution of Executive Systems Functions. Freeman, RQ., Giovanetti, T., Lamar, M., Cloude, B., Stern, R., Kaplan E., & Libon Neuropsychology, 14, (2000) Abstracts Characteristics of Digit Span in Alzheimer's disease patients. L Schram, D Loewenstein, A Acevedo, R Freeman, and E Mendelson Arch Clin Neuropsychology, November 2000; 15: Intrusion errors in learning and memory: a comparison of Alzheimer's disease and vascular dementia Arch Clin Neuropsychology, November 2000; 15: RQ Freeman PRESENTATIONS & LECTURES Behavioral Modification & the Neurologically Impaired. The Rehabilitation Hospital at Lee Memorial Hospital June/July 2001 Rehabilitation Psychology The Rehabilitation Hospital at Lee Memorial Hospital February, April, July 2001 Freeman, RQ., Loewenstein, DA., Acevedo, A., & Schram, L. Intrusion Errors in Learning & Memory: A comparison of Alzheimer s Disease and Vascular Dementia. Poster Presented at the National Academy of Neuropsychology, Orlando Florida (2000)

4 Neuropsychological Sequelea of Cardiac Disease. University of Miami School of Medicine Jackson Memorial Hospital-Neuropsychology Rounds November 1999 Neurobehavioral Changes in Alzheimer s Disease University of Miami School of Medicine-Jackson Memorial Hospital - Neuropsychology Rounds May 2000 RESEARCH EXPERIENCE: (Rater/ Sub-Investigator) A Phase II Double-Blind, Randomized, Dose Ranging, Placebo-Controlled, Multicenter, Safety and Efficacy Evaluation of Three Doses of XX XXXX in Patients with Mild to Moderate Dementia of the Alzheimer s Type A Fourteen-Week Placebo-Controlled Dose Response Efficacy and Safety Study of XXXXX in Early Parkinson s Disease Patient (Study for Proof of Concept in Early Parkinson s Disease of a Triple Reuptake Inhibitor, XX-XXX/SCEPTRE) A dose-ranging, placebo-controlled study of XXXX.XXXX-XX at the dose of 0.5 mg, 2 mg and 8 mg for 12 weeks in patients with mild to-moderate Alzheimer s Disease A Randomized, Double Blind, Placebo Controlled Trial to Evaluate the Safety and Efficacy of XX-XXXX 25 mg in Slowing the Progression o Alzheimer s Disease A ONE YEAR, MULITCENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO- CONTROLLED EVALUATION OF THE EFFICACY AND SAFETY OF DONEPEZIL HYDROCHLORIDE (XXXXX) IN SUBJECTS WITH MILD COGNITIVE IMPAIRMENT A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP PHASE 2 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF XXXXX IN SUBJECTS WITH MILD TO MODERATE ALZHEIMER S DISEASE Phase 3 Multicenter, Randomized, Double Blind, Placebo Controlled Study of the Effect of Daily Treatment with XXX XXX on Measures of Cognitive and Global Function in Subjects with Mild to Moderate Dementia of the Alzheimer s Type A randomized, multi-center, double-blind, placebo-controlled, 18-month study of the efficacy of XXXXXXXXXX in patients with mild-to moderate dementia of the Alzheimer s type An Open-label Exploratory Study with Memantine of Selected Measures of Volumetric MRI and Cognition in Patients with Moderate Dementia of the Alzheimer s Type SAFETY, TOLERABILITY, AND EFFICACY STUDY OF ORAL KETASYN (XX-XXXX) ADMINISTERED FOR NINETY DAYS IN SUBJECTS WITH PROBABLE ALZHEIMER S DISEASE OF MILD TO MODERATE SERVERTIY A MULTI-SITE, CROSS-SECTIONAL, NON TREATMENT, PROSPECTIVE TRIAL TO COLLECT BIO FLUIDS AND NEUROPSYCHIATRIC DATA FROM COGNITIVELY NORMAL ELDERLY SUBJECTS Open Label Study of the Effect of daily Treatment with XXX-XXXX in Subjects with Dementia of the Alzheimer s Type

5 Phase 3 Multinational, Randomized, Double Blind, Placebo Controlled Study of the Effect Of Daily Treatment with XXX-XXX on Measures of Cognition, Activities of Daily Living and Global Function in Subjects with Mild Dementia of the Alzheimer s Type A Prospective, 5-Week, Open-Label, Randomized, Multi-Center, Parallel-Group Study with a 20-week, Open-Label Extension Evaluating the Tolerability and Safety of Switching from Donepezil to an initial dose of 5cm² Rivastigmine Patch Formulation in Patients with Probable Alzheimer s Disease. A 28-Week Open Label Extension Study Evaluating the Safety and Tolerability of Donepezil hydrochloride (XXX) in Subjects with Mild Cognitive Impairment A Double-Blind, Randomized, Placebo Controlled Study of the Efficacy, Safety and Tolerability of 8 Week Treatment of XXXXXXX X mg (QHS) in Sleep Disturbed, Mild to Moderately Severe Alzheimer s Disease Subjects A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Safety and Efficacy Study of Oral XXXXXXX (XXX-XXX) in Alzheimer s Disease A Phase II, Randomized, Double-Blind, Placebo-Controlled, Dose Response Study of the Efficacy, Safety and Tolerability of XXXXXXXXXX as an XXXXXXXXXX Fast Dissolving Tablet in the Treatment Of Parkinson s Disease Patients Phase 3, parallel, placebo-controlled, dose/response, delayed-start 88 week study in patients with mild to moderate Alzheimer s disease A 76-week, prospective, open-label, multicenter study to evaluate the long-term effect of Exelon capsule and transdermal patch on worsening of the underlying motor symptoms of PD in patients with mild to moderately severe dementia associated with Parkinson s disease (PDD) SPECIAL INTERESTS: Miami Dolphins Cheerleader Miami Dolphins Ltd., Inc. Davie, FL Philadelphia Eagles Cheerleader Philadelphia Eagles, LLC